Fibrinolysis and metabolic disturbances in hemodialysis patients

Nieren- und Hochdruckkrankheiten

Volumn 30, Issue 11, 2001, Pages 505-515

  Opatrny K Jr ^a   Mares J ^a   Vit L ^a   Sefrna F ^a   Eiselt, J ^a   Opatrna S ^a   Racek, J ^a   Hejda, V ^a   Tomsu M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

1 deamino 8 D arginine vasopressin; Chronic renal failure; Dyslipoproteinemia; Hemodialysis; Plasminogen activator inhibitor; Tissue type plasminogen activator

Indexed keywords

APOLIPOPROTEIN A1; CREATININE; DESMOPRESSIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; FEMALE; FIBRINOLYSIS; HEMODIALYSIS; HUMAN; LIPID BLOOD LEVEL; MALE; METABOLIC DISORDER; REGRESSION ANALYSIS; THROMBOSIS; VASCULAR ACCESS;

EID: 0035192947     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus
2. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia
3. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients
4. The contribution of thrombosis to the clinical expression of coronary atherosclerosis
5. Mortality risk factors in patients treated by chronic hemodialysis. Report of the Diaphane collaborative study
6. Hyperinsulinemia predicts low tissue plasminogen activator activity in healthy population: The Northern Sweden MONICA Study
7. Low levels of the anticoagulant activity of protein C in patients with chronic renal insufficiency: An inhibitor of protein C is present in uremic plasma
8. Clinical epidemiology of cardiovascular disease in chronic renal disease
9. PAI-1 in thrombosis and arteriosclerosis
10. Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease
11. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor
12. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction
13. The effects of gemfibrozil upon the hypercoagulable state in dyslipidemic patients with chronic renal failure
14. Fibrinolytic activity in renal disease
15. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris
16. Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients
17. Plasminogen-activator inhibitor type I and coronary artery disease
18. On coagulation and fibrinolysis in uraemic patients on maintenance haemodialysis
19. Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells
20. Commonly measured laboratory variables in hemodialysis patients: Relationships among them and to death risk
21. Parathyroid hormone as a uremic toxin
22. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients
23. Hypertriglyceridemia and regulation of fibrinolytic activity
24. K/DOQI clinical practice guidelines for hemodialysis adequacy
25. K/DOQI clinical practice guidelines for vascular access. Update 2000
26. Residual plasminogen activator inhibitor activity after venous stasis as a criterion for hypofibrinolysis: A study in 83 patients with confirmed deep venous vein thrombosis
27. Fibrinolysis in patients with chronic renal failure after 1-deamino-8-D-arginine vasopressin
28. Hypofibrinolysis after stimulation by venous occlusion in hemodialysis patients and the effect of erythropoetin
29. Tissue-type plasminogen activator (tPA) and its inhibitor (PAI-1) in patients treated with continuous ambulatory peritoneal dialysis
30. Hemostasis disorders in chronic renal failure
31. Report on management of renal failure in Europe, XXII, 1991
32. Platelet function in patients on maintenance hemodialysis: Depressed or enhanced?
33. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator
34. Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome)
35. Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure
36. Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein
37. Plasma levels of 5-hydroxyindole-acetic acid in chronic renal insufficiency and their effect on platelet aggregation
38. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
39. Fibrinogen coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients
40. Hypercoagulable state in patients with hypercholesterolemia: Effects of pravastatin
41. Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis